In the last trading session, 12.38 million Novo Nordisk ADR (NYSE:NVO) shares changed hands as the company’s beta touched 0.66. With the company’s per share price at $79.33 changed hands at $3.87 or 5.13% during last session, the market valuation stood at $267.04B. NVO’s last price was a discount, traded about -86.75% off its 52-week high of $148.15. The share price had its 52-week low at $57.00, which suggests the last value was 28.15% up since then.
Analysts gave the Novo Nordisk ADR (NVO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.10. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NVO as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Novo Nordisk ADR’s EPS for the current quarter is expected to be 5.92.
Novo Nordisk ADR (NYSE:NVO) trade information
Instantly NVO was in green as seen at the end of in last trading. With action 11.87%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -7.78%, with the 5-day performance at 11.87% in the green. However, in the 30-day time frame, Novo Nordisk ADR (NYSE:NVO) is 20.62% up.
The consensus price target for the stock as assigned by Wall Street analysts is 158, meaning bulls need an upside of 49.79% from its current market value. According to analyst projections, NVO’s forecast low is 156 with 160 as the target high. To hit the forecast high, the stock’s price needs a -101.69% plunge from its current level, while the stock would need to soar -96.65% for it to hit the projected low.
Novo Nordisk ADR (NVO) estimates and forecasts
Year-over-year growth is forecast to reach 15.24% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 77.51B. 9 analysts are of the opinion that Novo Nordisk ADR’s revenue for the current quarter will be 83B. The company’s revenue for the corresponding quarters a year ago was 68.06B and 71.31B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 13.88%. The estimates for the next quarter sales put growth at 16.38%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.74%. The 2025 estimates are for Novo Nordisk ADR earnings to increase by 26.11%, but the outlook for the next 5-year period is at 18.92% per year.
NVO Dividends
Novo Nordisk ADR is expected to release its next quarterly earnings report in July. The 2.09% annual yield figure for the share gives it an annual dividend of 1.66. It is important to note, however, that the 2.09% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.
Novo Nordisk ADR (NYSE:NVO)’s Major holders
FMR LLC holds the second largest percentage of outstanding shares, with 0.4373% or 19.49 million shares worth $2.78 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were Goldman Sachs TRT II-Goldman Sachs GQG Part. Intl Opportunities Fd. and HARBOR FUNDS-Harbor Capital Appreciation Fund. With 4.82 shares estimated at $382.48 million under it, the former controlled 0.14% of total outstanding shares. On the other hand, HARBOR FUNDS-Harbor Capital Appreciation Fund held about 0.12% of the shares, roughly 4.22 shares worth around $334.71 million.
